9 RESULTS
COMMENT The choice of dose requires both a dose-ranging safety assessment (done with both single and multiple doses in Phase 1) and some reasonably definitive measure of efficacy (usually accomplished by dose-ranging studies in Phase 2, and not usually done in ...
COMMENT Drugs of course fail for many reasons—wrong mechanism, wrong target, wrong patient population, wrong dose, etc. In the case of solanezumab, if one accepts that the drug was "active," albeit with a very modest effect size (an assumption I share ...
COMMENT I first met Allen way back in 1976 while considering a residency in neurology at Duke. He was as brilliant, engaging, and provocative then as he was during our last meeting a few years ago. I think Allen enjoyed being outside the mainstream scientifically ...
COMMENT The paper is very interesting and further supports an important role for microglia in AD pathology. Here it appears that adaptive immunity (e.g., B-cell-derived antibodies) stimulates microglial phagocytosis/clearance of Aβ/amyloid in the mouse brain. ...
COMMENT Thanks to Jessica Shugart for writing a nice summary of our paper and for Martin Citron's thoughtful comments. I'd like to underscore that we are not stating that anti-tau monoclonal antibodies work to reduce tau pathology by an effector ...
COMMENT The paper by Hudry et al. is a beautiful extension of a paper my lab published almost nine years ago using viral vectors to deliver ApoE isoforms to the brains of PDAPP mice (see Dodart et al., 2005). In our study we showed that direct intrahippocampal ...
COMMENT Excellent summary of current knowledge. As to the initiating factors, I believe there is evidence for an entero-hepatic-immunological axis as the major generator of both nitrosative/oxidative stress and mitoenergetic stress in peripheral tissues, which ...
COMMENT Sam Gandy’s group’s study underscores an emerging role for isoprenoid-mediated regulation of APP processing and its possible relationship to Alzheimer disease pathogenesis. Over a year ago, we reported that GGPP, one of the isoprenoids synthesized in the ...
COMMENT Data from several groups has suggested that the Ab peptide can be transported from the brain to the blood and from the blood to the brain to a greater extent than would be expected unless there were specific transporters for Ab at the blood-brain barrier. ...
